Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCV Among Merck’s Gains With Schering, But Future Moves Still Murky

Executive Summary

As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies

You may also be interested in...



HCV Warning For ESAs Could Raise Questions For Pipeline Drugs

Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.

HCV Warning For ESAs Could Raise Questions For Pipeline Drugs

Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.

Schering’s Organon Grab Made Merck's Merger Magic Happen

Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel